- Home
- GDEV vs SGMT Comparison
GDEV vs SGMT Comparison
Compare GDEV & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GDEV | SGMT |
|---|---|---|
| Founded | 2009 | 2006 |
| Country | Cyprus | United States |
| Employees | 475 | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 203.3M | 169.4M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GDEV | SGMT |
|---|---|---|
| Price | $10.63 | $10.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $26.13 |
| AVG Volume (30 Days) | 13.3K | ★ 1.3M |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,000,000.00 |
| Revenue This Year | $8.56 | N/A |
| Revenue Next Year | $8.05 | N/A |
| P/E Ratio | $5.19 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.00 | $4.50 |
| 52 Week High | $42.20 | $11.15 |
Technical Indicators
Market Signals| Indicator | GDEV | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 38.20 | 68.92 |
| Support Level | N/A | $6.16 |
| Resistance Level | $13.60 | N/A |
| Average True Range (ATR) | 0.64 | 0.69 |
| MACD | -0.15 | 0.12 |
| Stochastic Oscillator | 22.34 | 77.50 |
Price Performance
Historical ComparisonAbout GDEV GDEV Inc.
GDEV Inc is a gaming and entertainment holding company that oversees a portfolio of studios focused on developing and publishing live-service games across a range of platforms and genres. Its portfolio includes studios specializing in mobile, browser, and PC games, as well as captivating IPs spanning various genres.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.